logo-loader
Biomerica, Inc.

Biomerica Inc in clinical trials for their diagnostic-guided therapy that helps identify IBS

Biomerica Inc (NASDAQ:BMRA, OTCUS:BMRA) CEO Zack Irani-Cohen tells Proactive Investors the global biomedical company that develops, manufacturers, and markets advanced diagnostic products that tells a doctor how to treat a patient.

Biomerica focuses on products for gastrointestinal disease including IBS. The Biomerica InFoods IBS product identifies patient specific foods that when removed may alleviate a patient's IBS symptoms. Irani-Cohen says Biomerica is in clinical trials for their diagnostic-guided therapy, and could be taking their product to the market in the next few years.

Quick facts: Biomerica, Inc.

Price: $2.94

Market: NASDAQ
Market Cap: $28.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Great Bear Resources releases more positive drill results...

Great Bear Resources (CVE: GBR) President and CEO Chris Taylor joined Steve Darling from Proactive Vancouver to discuss their latest assay results from the drill program on the Dixie Project in Red Lake.  Taylor discusser the results from the Hinge and Dixie Limb zones and also gave...

18 hours, 46 minutes ago

2 min read